Baird initiates Abbott stock coverage with Outperform rating

Baird initiated coverage of Abbott (ABT) with an Outperform rating and a $121 price target, implying ~33% upside from $90.74, citing steady expected 6-8% top-line and earnings growth. The firm projects Abbott’s medical device segment will grow ~8-10% above peers, while placing fiscal 2026 estimates at the low end of guidance amid near-term diagnostics and China headwinds before clearer upside in 2027-2028. Separately, Abbott secured CE Mark approval for its Libre Duo and Libre Duo 10 Day continuous monitoring systems and announced a licensing agreement to incorporate ALZpath’s phosphorylated Tau 217 antibody into an Alzheimer’s in vitro diagnostic test.

Analysis

Healthcare is likely to outperform on a weak labor print, but the cleaner expression here is not a blanket sector long; it is a quality-growth rotation into diversified medtech with multiple shots on goal. ABT’s setup is attractive because incremental upside can come from mix, not just volume, which matters in a slower-growth macro tape where investors pay for durability and cash conversion. Relative to faster-growing but more single-product peers such as DXCM, the market may be underpricing ABT’s ability to compound without needing a single end-market to work perfectly.

The second-order read-through is that diagnostics and diabetes-monitoring adjacencies can create cross-selling leverage across hospitals, labs, and payers, which tends to be more durable than headline product launches suggest. If the new product cadence is real, the biggest beneficiaries are the suppliers with broad distribution and the ability to bundle service/software, while smaller point-solution competitors face higher commercialization friction and potentially weaker pricing power. That said, the near-term upside is more about multiple support than immediate earnings inflection; if reimbursement, adoption, or China normalization lag, this remains a 1-2 quarter trading story rather than a clean re-rating.

Contrarian view: the consensus is probably too focused on the price target upside and not enough on timing. These kinds of approvals and partnerships often matter most 6-18 months out, and the stock can stay range-bound until the next print proves traction in revenue or margin. The move would be falsified if the next two quarters show no acceleration in core device growth or if lapping headwinds overwhelm the launch cycle; on the other hand, falling yields and a defensive bid can make the stock work even before the fundamentals fully show up.

Key Decisions for Investors

• Long ABT on pullbacks for a 3-6 month hold; favor stock over calls unless you have a clear earnings catalyst, since the setup is more about steady re-rating than a binary event.
• Pair trade: long ABT / short DXCM over the next 1-3 months to express diversified execution vs. single-product valuation risk; cover the short if DXCM reaccelerates growth or ABT misses device momentum.
• Small tactical long EXAS on confirmation of colorectal screening adoption, not on the headline alone; use it as a 2-4 month trade if reimbursement/volume data validates the endorsement.
• Set a watch item on ABT’s next quarterly device growth and margin commentary; if organic growth does not hold the mid-single digits or management pushes the upside story out another year, take profits and reassess.